PubRank

A Trial In Patients With Advanced Cancer And Leukemia

Clinical Trial ID NCT00878189

PubWeight™ 21.53‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00878189

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol 2015 2.02
2 Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 2013 1.96
3 Notch inhibitors for cancer treatment. Pharmacol Ther 2013 1.55
4 Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2010 1.40
5 Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch. Cell Cycle 2012 1.26
6 Gamma secretase inhibitors of Notch signaling. Onco Targets Ther 2013 1.21
7 Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin Cell Dev Biol 2012 1.17
8 Targeting cancer stem cells: a new therapy to cure cancer patients. Am J Cancer Res 2012 1.11
9 Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. Nat Rev Neurosci 2013 1.11
10 Notch3 activation promotes invasive glioma formation in a tissue site-specific manner. Cancer Res 2011 1.01
11 Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget 2015 0.97
12 Notching on Cancer's Door: Notch Signaling in Brain Tumors. Front Oncol 2015 0.95
13 Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer. Cancer Growth Metastasis 2015 0.90
14 Notch signaling: its roles and therapeutic potential in hematological malignancies. Oncotarget 2016 0.87
15 A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J 2015 0.86
16 Therapeutics formulated to target cancer stem cells: Is it in our future? Cancer Cell Int 2011 0.83
17 Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016 0.81
18 The challenge of targeting notch in hematologic malignancies. Front Pediatr 2014 0.78
19 Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms. Oncotarget 2015 0.76
20 Targeting the perpetrator: breast cancer stem cell therapeutics. Curr Drug Targets 2010 0.75
Next 100